Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) – Equities research analysts at Cantor Fitzgerald cut their FY2022 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, November 22nd. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($0.91) per share for the year, down from their previous estimate of ($0.70). Cantor Fitzgerald has a “Overweight” rating and a $12.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.80) per share. Cantor Fitzgerald also issued estimates for Fennec Pharmaceuticals’ FY2023 earnings at ($0.78) EPS.
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) last posted its quarterly earnings data on Friday, November 11th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.14).
Fennec Pharmaceuticals Trading Down 0.2 %
Shares of FENC stock opened at $9.51 on Thursday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 10.30 and a current ratio of 10.30. Fennec Pharmaceuticals has a 52-week low of $3.82 and a 52-week high of $9.87. The company has a market capitalization of $249.54 million and a PE ratio of -11.60. The business’s fifty day moving average is $8.13 and its 200 day moving average is $6.91.
Institutional Trading of Fennec Pharmaceuticals
A number of institutional investors have recently modified their holdings of the company. UBS Group AG boosted its holdings in shares of Fennec Pharmaceuticals by 4,742.2% during the third quarter. UBS Group AG now owns 3,099 shares of the company’s stock worth $26,000 after purchasing an additional 3,035 shares during the period. Hartford Financial Management Inc. boosted its holdings in shares of Fennec Pharmaceuticals by 14.3% during the third quarter. Hartford Financial Management Inc. now owns 39,848 shares of the company’s stock worth $323,000 after purchasing an additional 5,000 shares during the period. Jane Street Group LLC purchased a new stake in Fennec Pharmaceuticals in the third quarter worth about $118,000. JPMorgan Chase & Co. lifted its holdings in Fennec Pharmaceuticals by 23,280.0% in the first quarter. JPMorgan Chase & Co. now owns 16,366 shares of the company’s stock worth $91,000 after buying an additional 16,296 shares during the period. Finally, DG Capital Management LLC lifted its holdings in Fennec Pharmaceuticals by 4.4% in the first quarter. DG Capital Management LLC now owns 1,210,638 shares of the company’s stock worth $6,780,000 after buying an additional 51,249 shares during the period. 43.29% of the stock is currently owned by hedge funds and other institutional investors.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
- Get a free copy of the StockNews.com research report on Fennec Pharmaceuticals (FENC)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.